These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26974491)

  • 1. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation.
    Kamisato C; Furugohri T; Morishima Y
    Thromb Res; 2016 May; 141():77-83. PubMed ID: 26974491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
    Furugohri T; Sugiyama N; Morishima Y; Shibano T
    Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
    Furugohri T; Morishima Y
    Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
    Perzborn E; Heitmeier S; Buetehorn U; Laux V
    J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
    Morishima Y; Kamisato C; Honda Y
    Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
    Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
    Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
    Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
    Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.
    Yegneswaran S; Nguyen PM; Gale AJ; Griffin JH
    Thromb Haemost; 2009 Jan; 101(1):55-61. PubMed ID: 19132189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
    Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.
    Gierula M; Salles-Crawley II; Santamaria S; Teraz-Orosz A; Crawley JTB; Lane DA; Ahnström J
    J Thromb Haemost; 2019 Dec; 17(12):2056-2068. PubMed ID: 31364267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
    Nishioka J; Ido M; Hayashi T; Suzuki K
    Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
    Incampo F; Carrieri C; Semeraro N; Colucci M
    Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.
    Mattsson C; Menschik-Lundin A; Nylander S; Gyzander E; Deinum J
    Thromb Res; 2001 Dec; 104(6):475-86. PubMed ID: 11755958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
    Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
    Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
    Shirasaki Y; Morishima Y; Shibano T
    Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X.
    Al Dieri R; Bloemen S; Kelchtermans H; Wagenvoord R; Hemker HC
    J Thromb Haemost; 2013 Mar; 11(3):503-11. PubMed ID: 23294934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
    Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C.
    Gale AJ; Xu X; Pellequer JL; Getzoff ED; Griffin JH
    Protein Sci; 2002 Sep; 11(9):2091-101. PubMed ID: 12192065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.